Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Running, not enrolling

Conditions studied: Myocardial Infarction

In brief

The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.

Key facts

Study ID

NCT04076813

Run by

Chiesi USA, Inc.

People needed

5050

Starts

2019-10-16

Expected to finish

2025-06-30

Last updated by the study team

2025-06-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Regents of the University of California on behalf of its San Diego campus — La Jolla, California, United States
• Christiana Care Health Services, Inc. — Newark, Delaware, United States
• University of Florida — Gainesville, Florida, United States
• Kootenai Hospital District dba Kootenai Health — Coeur d'Alene, Idaho, United States
• MedStar Health Research Institute, Inc. — Hyattsville, Maryland, United States
• The Brigham and Women's Hospital, Inc. — Boston, Massachusetts, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Washington University — St Louis, Missouri, United States
• The Trustees of Columbia University in the City of New York — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.